Gaya Herald

Type 2 Diabetes Overview

Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.

“Type 2 Diabetes Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.

The Type 2 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Type 2 Diabetes Pipeline Report:

• Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years. Type 2 Diabetes Key players such as – Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co., Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others, are developing therapies for the Type 2 Diabetes treatment 

• Type 2 Diabetes Emerging therapies such as – type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years
• In Jan 2023, FDA approved Brenzavvy to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise  
• In May 2021, Novo Nordisk initiated 26-week trial comparing the effect and safetyof once weekly insulin icodec and once daily insulin glargine 100 Units/mL, both in combination with bolus insulin with or without non-insulin anti-diabetic drugs, in subjects with Type 2 Diabetes on a Basal-bolus Regimen

Route of Administration

Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Type 2 Diabetes Pipeline Therapeutics Assessment

• Type 2 Diabetes Assessment by Product Type
• Type 2 Diabetes By Stage and Product Type
• Type 2 Diabetes Assessment by Route of Administration
• Type 2 Diabetes By Stage and Route of Administration
• Type 2 Diabetes Assessment by Molecule Type
• Type 2 Diabetes by Stage and Molecule Type

DelveInsight’s Type 2 Diabetes Report covers around 100+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Type 2 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 2 Diabetes are – AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, Thermalin Inc., Adocia SAS, Hanmi Pharmaceuticals Co Ltd, Pfizer Inc., Akston Biosciences Corp., Algiax Pharmaceuticals GmbH, Biocon Ltd, and Others

Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:

• Research programme: type 2 diabetes mellitus therapeutics Abarceo Pharma
• CT996: Carmot Therapeutics
• NRDN-101: Neurodon
• Sotagliflozin: Lexicon Pharmaceuticals
• ECC5004: Eccogene
• ORMD0801: Oramed Pharmaceuticals
• LY3209590: Eli lily and Company
• HM12460A: Hanmi Pharmaceuticals
• KN056: Suzhou Alphamab Co., Ltd.
• XW014: Sciwind Biosciences
• AMG 133: Amgen
• RGT001-075: Regor Pharmaceuticals
• HR17031: Jiangsu Hengrui Medicine Co.
• CPL207280: Celon Pharma
• HM14220: Hanmi Pharmaceuticals
• ORMD-0801: Oramed Pharmaceuticals
• LY-3209590: Eli Lilly and Company
• Insulin icodec: Novo Nordisk

Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight

Type 2 Diabetes Pipeline Analysis:

The Type 2 Diabetes pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
• Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies

Type 2 Diabetes Pipeline Market Drivers

• Increasing Prevalence
• Government bodies are collaborating with major market players for the launch of new products
• Increase in the demand for insulin over the world

Type 2 Diabetes Pipeline Market Barriers

• Side-effects associated with the treatment of Type 2 Diabetes
• A lack of knowledge about a healthy diet, medication initiation

Scope of Type 2 Diabetes Pipeline Drug Insight    

• Coverage: Global
• Key Type 2 Diabetes Companies: Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co., Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others
• Key Type 2 Diabetes Therapies: type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others
• Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
• Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers 

Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services